Therapeutics: Matrix metalloproteinase 2 (MMP2); MMP9; MMP14

Cell and mouse studies identified an inhibitor of MMP2, MMP9, and MMP14 that could help treat cancer. Chemical synthesis and testing in an MMP binding assay of sulfonamide hydroxamate analogs identified a compound that inhibited MMP2, MMP9 and MMP14 with IC50 values of 0.67, 0.43 and 3.9 nM, respectively. In human umbilical vein endothelial cells, the compound decreased endothelial cell migration compared with the parent sulfonamide hydroxamate. In a mouse model of angiogenesis, the compound decreased angiogenesis compared with vehicle. Next steps could include testing the compound in cancer models...